11 July 2022

Fragments in the clinic: HTL9936

Of the 50+ fragment-derived drugs that have entered the clinic, only two (both from Sosei Heptares) target transmembrane proteins, reflecting the difficulty of structure-based design for this hard-to-crystallize class of proteins. The story behind one of them was published late last year in Cell by Malcom Weir, Andrew Tobin, and a large group of collaborators.
 
The researchers were interested in the M1 muscarinic acetylcholine receptor, which is involved in memory and learning. By activating the receptor the hope is to be able to treat symptoms associated with Alzheimer’s disease. The M1 receptor has been a long-standing target for this disease, but previous drugs have caused side effects ranging from salivation and sweating to gastrointestinal distress and seizures. The M1 receptor is one of five closely related subtypes, and some of the side effects have been attributed to hitting the M2 and M3 receptors. However, the M1 receptor itself may also not be entirely innocent, so the goal was to develop a partial agonist, the idea being that this may be more effective in the brain, where the M1 receptor is highly expressed, while sparing other tissues where the M1 receptor is rarer.
 
The campaign began with a virtual screen of 1.6 million molecules (with molecular weights up to 400 Da) against a homology model of the human M1 receptor bound to a known agonist. This led to the purchase of 322 compounds, of which 16 were active in a cell-based functional assay, including compound 4. Fragment growing led to compound 6 and ultimately to HTL9936, which is selective for M1 over M2, M3, and M4 receptors. It also showed no significant agonism against a panel of 62 GPCRs even at 10 µM concentration.
 

Sosei Heptares pioneered the use of mutagenesis to stabilize specific conformational states of GPCRs, and this process was used to produce co-crystals with HTL9936 to understand its binding mode. Like other reported agonists, which were also characterized crystallographically, HTL9936 binds in the orthosteric site of the M1 receptor, but the increased size of the homopiperidine ring relative to other ligands provides selectivity over other receptors such as M2.
 
HTL9936 was tested in mice, rats, dogs, and cynomolgus monkeys, and in general showed good safety and brain penetration. The molecule even showed cognitive benefits in a mouse model of neurodegeneration and in aged beagles. It did cause an increase in heart rate and blood pressure in dogs, and there was a single convulsive episode, but only at a very high dose.
 
The paper also summarizes the results of human clinical trials which demonstrated that HTL9936 is well tolerated up to 100 mg doses, though at higher doses sweating, salivation, and changes in heart rate and blood pressure were observed. A small trial in healthy elderly people did not show any improvement in memory tasks, though functional magnetic resonance imaging studies did show that the molecule activated regions of the brain associated with cognition.
 
And that’s where the story ends. The Sosei Heptares website does not list HTL9936, though a different M1 receptor agonist (HTL0018318) is described. This paper also illustrates the long gap that can occur between research and publication: ClinicalTrials.gov lists three Phase 1 studies for HTL0009936, one of which began in 2013, and all of which ended by early 2017. Like most approaches to Alzheimer’s disease that have been tested, perhaps targeting the M1 receptor is a dead end. But reaching that conclusion requires highly selective chemical probes. Kudos to the team at Sosei Hetpares for their efforts.

2 comments:

Christophe said...

HTL0018318's history is described at ALZFORUM:
https://www.alzforum.org/therapeutics/htl0018318

Dan Erlanson said...

Thanks Christophe - another reader sent me this reference, which lists the structure of HTL0018318 as ethyl (3-endo)-3-(3-oxo-2,8-diazaspiro[4.5]dec-8-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate hydrochloride, close enough to HTL9936 to suggest similar parentage.